Sarah Chen, MD, PhD
Principal Investigator · Oncology · Stanford
Oncology PI | Phase II/III trial lead (n=847) | Translating immunotherapy research into clinical protocols that reduce recurrence by 34%
I lead a 12-person translational oncology lab at Stanford investigating checkpoint inhibitor resistance mechanisms. My team's Phase II data (ASCO 2024) showed 34% reduction in 18-month recurrence across HER2+ cohorts. I collaborate with industry partners on biomarker-driven trial design and speak at ESMO, AACR, and ASH annually.
Checkpoint Resistance in HER2+ Breast Cancer — Nature Medicine, 2024
Phase II: Pembrolizumab + Trastuzumab (n=847) — NEJM, 2023

Researchers who found
the room they deserved.
Rigorous as peer review.
Faster than a grant cycle.
Every ProfileUp engagement follows the same editorial protocol used in clinical publishing — hypothesis, design, iteration, release.

"The closest thing to having a science communicator on staff."
— Dr. Aisha Patel, Neuroscience PI · UCSF